CymitQuimica logo

CAS 960539-70-2

:

Daprodustat

Description:
Daprodustat is a small molecule drug primarily developed for the treatment of anemia associated with chronic kidney disease (CKD). It functions as a hypoxia-inducible factor prolyl hydroxylase inhibitor, which enhances erythropoiesis by mimicking the physiological response to low oxygen levels. This mechanism stimulates the production of erythropoietin, a hormone that promotes red blood cell formation. Daprodustat is characterized by its ability to increase hemoglobin levels without the need for traditional erythropoiesis-stimulating agents, potentially offering a safer alternative with a lower risk of hypertension and cardiovascular events. The compound is administered orally and has been evaluated in clinical trials for its efficacy and safety profile. Its pharmacokinetics involve absorption, metabolism, and excretion that are influenced by various factors, including renal function. Overall, daprodustat represents a novel approach in managing anemia in CKD patients, aiming to improve quality of life and reduce the need for blood transfusions.
Sort by

Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 3 products.
  • Daprodustat

    CAS:
    <p>Daprodustat (GSK1278863) is a HIF-prolyl hydroxylase inhibitor.</p>
    Formula:C19H27N3O6
    Purity:97% - 99.82%
    Color and Shape:Solid
    Molecular weight:393.43
  • Daprodustat

    CAS:
    <p>Applications Daprodustat is a novel HIF (Hypoxia inducible factor)-prolyl hydroxylase inhibitor.<br>References Olson, E., et al.: Vasc. Med., 19, 473 (2014);<br></p>
    Formula:C19H27N3O6
    Color and Shape:Off-White
    Molecular weight:393.43

    Ref: TR-D193368

    10mg
    160.00€
    25mg
    285.00€
    100mg
    911.00€
  • GSK 1278863

    Controlled Product
    CAS:
    <p>Inhibitor of HIF-prolyl hydroxylase isozymes PHD1, PHD2 and PHD3 with Ki in nanomolar range. The compound mimics the binding of N-oxalylglycine, chelates catalytic iron and prevents substrate entry into catalytic site. Inhibition of PHD enzymes leads to stabilization of hypoxia-induced factors HIF1α and HIF2α, followed by the production of erythropoietin (EPO).</p>
    Formula:C19H27N3O6
    Purity:(%) Min. 95%
    Color and Shape:Powder
    Molecular weight:393.43 g/mol

    Ref: 3D-BG166670

    10mg
    244.00€
    25mg
    382.00€
    50mg
    553.00€
    100mg
    886.00€
    250mg
    1,707.00€